Non-small cell lung cancer

News

Strike three for Novartis' canakinumab as lung cancer therap...

Expectations for Novartis' canakinumab as an oncology therapy were already fading fast, and have now been nixed after a third phase 3 trial in non-small cell lung cancer (NSCLC) failed to m

News

Tagrisso paired with Hutchmed drug clears lung cancer test

EGFR inhibitors like AstraZeneca's Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations.

News

AZ takes aim at BMS' lead in neoadjuvant NSCLC

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small cell lung cancer, AstraZeneca is looking to encroach on its territory.

News

Roche's Tecentriq extends lead over Keytruda in adjuvant NSC...

While Merck & Co's Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there's one category where it lags behind Roche's Tecentriq – treatment of early

News

Mirati heads for FDA verdict on KRAS drug with new data

Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete with first-to-market rival Lumakras from Amgen.

News

Roche's TIGIT ambitions take another blow

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuste

Strike three for Novartis' canakinumab as lung cancer therap...

Tagrisso paired with Hutchmed drug clears lung cancer test

AZ takes aim at BMS' lead in neoadjuvant NSCLC

Roche's Tecentriq extends lead over Keytruda in adjuvant NSC...

Mirati heads for FDA verdict on KRAS drug with new data

Roche's TIGIT ambitions take another blow

AZ claims another win for Imfinzi in frontline liver cancer

Using AI-driven synthetic personas to take your insights fur...

Non-small cell lung cancer

Editor's Picks